LONCAR Cancer ETF

Top category "Fund Providers" is hidden please check in administration to make it visible

LONCAR Cancer ETF
  • Pininvest Analysis

 

The Loncar Cancer Immunotherapy ETF is made up of a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system.

Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care.

By developing immunotherapies that are more effective and may deliver a better quality of life than currently available medicines, innovative immunotherapy companies may be making a difference for courageous patients who battle cancer.

Loncar ETF seeks to support this important work and its positive impact on society

The complete list of 25 CNCR constitutents presented in the theme is not weighted; performance and volatility are calculated for informative purpose only - assuming one share of each component had been invested at the beginning of the selected period

More about LONCAR CNCR, the Cancer Immunotherapy ETF

LONCAR Cancer ETF • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Vol. Risk Contrib. MDD
 
Adaptimmune Therapeutics ADAP NASDAQ Health Care Biopharmaceuticals USD 4.52 476 M -7.0% 141%   6% -87%
Aduro Biotech ADRO NASDAQ Health Care Biopharmaceuticals USD 1.40 - -48.1% 85%   2% -79%
Arcus Biosciences RCUS NYSE Health Care Clinical trial work USD 10.23 469 M 1.8% 69%   5% -52%
Astrazeneca PLC (ADR) AZN NYSE Health Care Drug Manufacturers - Diversified USD 51.33 130 B 44.3% 21%   1% -13%
Atara Biotherapeutics ATRA NASDAQ Health Care Biopharmaceuticals USD 15.03 814 M -59.7% 62%   2% -74%
BeiGene BGNE NASDAQ Health Care Gene Editing - Cell Therapies USD 170.36 10 B 18.9% 53%   3% -23%
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 98.04 5.4 B -24.6% 50%   3% -55%
Bristol-Myers Squibb BMY NYSE Health Care Drug Manufacturers - Diversified USD 66.72 109 B 36.5% 21%   1% -21%
Cellectis (ADR) CLLS NASDAQ Health Care Gene Editing - Cell Therapies USD 18.24 774 M 9.0% 46%   3% -53%
CytomX Therapeutics CTMX NASDAQ Health Care Biopharmaceuticals USD 7.46 339 M -55.5% 70%   2% -73%
Dynavax Technologies DVAX NASDAQ Health Care Biopharmaceuticals USD 6.03 506 M -50.0% 67%   1% -78%
Fate Therapeutics FATE NASDAQ Health Care Biopharmaceuticals USD 25.65 1.9 B 59.9% 70%   9% -40%
Five Prime Therapeutics FPRX NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 5.31 193 M -52.5% 65%   2% -77%
Gilead Sciences GILD NASDAQ Health Care Biopharmaceuticals USD 62.98 80 B -5.3% 21%   1% -12%
Iovance Biotherapeutics IOVA NASDAQ Health Care Biopharmaceuticals USD 23.88 3.0 B 153.5% 66%   13% -31%
MacroGenics MGNX NASDAQ Health Care Biopharmaceuticals USD 11.26 551 M -8.5% 99%   5% -69%
Merck & Company MRK NYSE Health Care Drug Manufacturers - Diversified USD 90.97 232 B 22.9% 18%   1% -12%
Mirati Therapeutics, Inc. MRTX NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 97.05 3.8 B 49.5% 63%   6% -35%
MorphoSys MOR NASDAQ Health Care Biopharmaceuticals USD 32.88 4.2 B 14.4% 47%   2% -26%
Nektar Therapeutics NKTR NASDAQ Health Care Clinical trial work USD 22.48 4.0 B -51.3% 70%   2% -66%
Novartis NVS NYSE Health Care Drug Manufacturers - Diversified USD 95.93 222 B 22.9% 20%   1% -22%
Sorrento Therapeutics SRNE NASDAQ Health Care Biopharmaceuticals USD 4.26 604 M 85.2% 124%   15% -76%
Xencor XNCR NASDAQ Health Care Clinical trial work USD 37.55 2.1 B 11.6% 52%   4% -29%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 4.64 840 M 104.4% 62%   9% -43%
Zymeworks ZYME NYSE Health Care Clinical trial work USD 49.12 1.9 B 208.9% 45%   5% -10%